Related Experiment Video
Updated: Jul 30, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Unusual hypersensitivity to warfarin in a critically ill patient
1Department of Hospital Pharmacy, Shiga University of Medical Science, Seta, Otsu, Japan. konishi@belle.shiga-med.ac.jp
Abstract:
A patient was admitted to the intensive care unit because of respiratory failure, and warfarin therapy was started at 2 mg/day for the treatment of pulmonary embolism, together with other medications. Despite the low dosage of warfarin, international normalized ratio (INR) was markedly elevated from 1.15 to 11.28 for only 4 days, and bleeding symptoms concurrently developed. Vitamin K2 was infused along with discontinuation of warfarin. One day later, the INR was found to have decreased, and bleeding was also improved. An objective causality assessment indicated a probable relationship between clotting abnormality and warfarin administration, although the degree of elevation of the INR was unusual in the light of the daily warfarin dose and duration of its exposure. Based on the clinical status of the patient, it was suspected that several conditions contributed to the abnormal hypersensitivity to warfarin. Contributory factors probably included pharmacokinetic interactions with co-administrated drugs, vitamin K deficiency caused by decreased dietary intake, reduced gut bacterial production, impaired intestinal absorption and hepatic synthetic capacity, and increased consumption of clotting factors. In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid fatal haemorrhage after initiating warfarin therapy regardless of the dosage.
Insights
Critically ill patients on warfarin may experience dangerous international normalized ratio (INR) elevations even at low doses. Close coagulation monitoring is essential to prevent fatal bleeding events in intensive care settings.
Area of Science:
- Pharmacology
- Critical Care Medicine
- Hematology
Background:
- Warfarin is a common anticoagulant used for conditions like pulmonary embolism.
- Critically ill patients often have multiple comorbidities and drug interactions.
- Standard warfarin dosing may lead to unpredictable anticoagulation in intensive care unit (ICU) settings.
Observation:
- A patient in the ICU receiving low-dose warfarin (2 mg/day) for pulmonary embolism developed a markedly elevated international normalized ratio (INR) from 1.15 to 11.28 within 4 days.
- The patient concurrently experienced bleeding symptoms.
- Despite the low warfarin dose, the INR elevation was unusually high.
Findings:
- A probable relationship was identified between the clotting abnormality and warfarin administration.
- Suspected contributing factors to warfarin hypersensitivity included pharmacokinetic interactions, vitamin K deficiency (due to decreased intake, reduced gut bacteria, impaired absorption), and reduced hepatic synthetic capacity.
- Increased consumption of clotting factors was also considered.
Implications:
- Critically ill patients require close monitoring of coagulation capacity during warfarin therapy, irrespective of dosage.
- Unusual INR elevations and bleeding risk necessitate prompt intervention, such as vitamin K administration.
- This case highlights the complexity of anticoagulation management in the ICU and the need for individualized patient assessment.
Related Concept Videos
Therapeutic Index
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug toxicity: Idiosyncratic Reactions
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
